Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IMPDH2 | P12268 | 20/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6172224 | 0.93 | IMPDH2 (0.89) | IMPDH2 | |
| SCHEMBL1473083 | 0.89 | IMPDH2 (0.80) | IMPDH2 | |
| SCHEMBL1475997 | 0.88 | IMPDH2 (0.81) | IMPDH2 | |
| SCHEMBL7722777 | 0.87 | IMPDH2 (0.81) | IMPDH2 | |
| SCHEMBL6639762 | 0.81 | IMPDH2 (0.68) | IMPDH2 | |
| SCHEMBL16421380 | 0.80 | IMPDH2 (0.55) | IMPDH2 | |
| SCHEMBL21757560 | 0.79 | IMPDH2 (0.74) | IMPDH2 | |
| SCHEMBL1473186 | 0.79 | IMPDH2 (1.00) | IMPDH2 | |
| SCHEMBL1475072 | 0.79 | IMPDH2 (1.00) | IMPDH2 | |
| SCHEMBL14518599 | 0.78 | IMPDH2 (0.68) | IMPDH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1126843-A4 | COMPOUNDS DERIVED FROM AN AMINE NUCLEUS THAT ARE INHIBITORS OF IMPDH ENZYME | BRISTOL MYERS SQUIBB CO (US) | 2005-06-15 | — | — | EP | disclosed |
| EP-1448187-A4 | COMPOUNDS DERIVED FROM AN AMINE NUCLEUS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | BRISTOL MYERS SQUIBB CO (US) | 2005-05-25 | — | — | EP | disclosed |
| EP-1448187-A2 | COMPOUNDS DERIVED FROM AN AMINE NUCLEUS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | Bristol-Myers Squibb Company (US) | 2004-08-25 | — | — | EP | disclosed |
| US-6596747-B2 | For therapy of diseases associdated with Factor VIIa and or inosine monophosphate dehydrogenase (IMPDH) | BRISTOL-MYERS SQUIBB COMPANY | 2003-07-22 | — | — | US | disclosed |
| WO-2003047512-A2 | COMPOUNDS DERIVED FROM AN AMINE NUCLEUS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-06-12 | — | — | WO | disclosed |
| US-20020143176-A1 | Compounds derived from an amine nucleus and pharmaceutical compositions comprising same | BRISTOL-MYERS SQUIBB COMPANY | 2002-10-03 | — | — | US | disclosed |
| US-6399773-B1 | AUTOIMMUNE DISEASE; TRANSPLANTING ORGANS | BRISTOL-MYERS SQUIBB CO. | 2002-06-04 | — | — | US | disclosed |
| EP-1126843-A1 | COMPOUNDS DERIVED FROM AN AMINE NUCLEUS THAT ARE INHIBITORS OF IMPDH ENZYME | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-08-29 | — | — | EP | disclosed |
| WO-2000025780-A1 | COMPOUNDS DERIVED FROM AN AMINE NUCLEUS THAT ARE INHIBITORS OF IMPDH ENZYME | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020143176-A1 | Compounds derived from an amine nucleus and pharmaceutical compositions comprising same | IMPDH1, IMPDH2, IMPA1 | IMPDH2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.